Ocular Pain - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Ocular Pain - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Ocular Pain - Pipeline Review, H2 2016', provides an overview of the Ocular Pain pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Ocular Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Pain and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ocular Pain
- The report reviews pipeline therapeutics for Ocular Pain by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Ocular Pain therapeutics and enlists all their major and minor projects
- The report assesses Ocular Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Ocular Pain

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Ocular Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table Of Content

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Ocular Pain Overview 7
Therapeutics Development 8
Pipeline Products for Ocular Pain - Overview 8
Ocular Pain - Therapeutics under Development by Companies 9
Ocular Pain - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Ocular Pain - Products under Development by Companies 13
Ocular Pain - Companies Involved in Therapeutics Development 14
D. Western Therapeutics Institute, Inc. 14
InSite Vision Incorporated 15
Kala Pharmaceuticals, Inc. 16
Ocular Therapeutix, Inc. 17
Reata Pharmaceuticals, Inc. 18
Sylentis S.A.U. 19
Valeant Pharmaceuticals International, Inc. 20
Ocular Pain - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
(bromfenac sodium + dexamethasone acetate) - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
bromfenac sodium - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
dexamethasone acetate SR - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Drug for Ocular Pain - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
ISV-705 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
ketorolac tromethamine - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
loteprednol etabonate - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
loteprednol etabonate next generation - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
NT-71 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
NT-72 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
omaveloxolone - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
RX-10045 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecules to Block NaV1.7 Channel for Pain, Ocular Pain and Pruritus - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
SYL-1001 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Ocular Pain - Dormant Projects 59
Ocular Pain - Product Development Milestones 60
Featured News & Press Releases 60
Apr 09, 2016: Sun Pharma Receives USFDA Approval For BromSite 60
Mar 14, 2016: Sylentis Reports Positive Phase II Results With SYL1001 in Treating Ocular Pain Related to Dry Eye Syndrome 60
Sep 02, 2015: InSite Vision Named in BromSite Patent Lawsuit; Company Believes Lawsuit Is Without Merit 61
Aug 17, 2015: InSite Vision Announces FDA Acceptance of NDA Filing for BromSite 61
Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery 62
May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 62
Apr 25, 2013: Pharm-Olam Completes Phase III Ophthalmology Study Of InSite Vision's Bromsite 63
Mar 18, 2013: InSite Vision Reports Positive Phase III Results Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 63
Jan 10, 2013: InSite Vision Completes Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 64
Nov 29, 2012: InSite Vision Completes Patient Enrollment In Phase III Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 64
Jul 31, 2012: InSite Vision Initiates First Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 65
Mar 22, 2011: InSite Vision Announces Positive Phase I/II Results For ISV-303 For Reduction Of Pain And Inflammation After Cataract Surgery 66
Jan 05, 2011: InSite Vision Completes Patient Enrollment In ISV-303 Phase I/II Clinical Study For Post-Surgical Ocular Pain And Swelling 67
Dec 15, 2009: InSite Vision To Advance New Ocular Anti-Inflammatory Candidate 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70

List Of Tables

Number of Products under Development for Ocular Pain, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Ocular Pain - Pipeline by D. Western Therapeutics Institute, Inc., H2 2016 14
Ocular Pain - Pipeline by InSite Vision Incorporated, H2 2016 15
Ocular Pain - Pipeline by Kala Pharmaceuticals, Inc., H2 2016 16
Ocular Pain - Pipeline by Ocular Therapeutix, Inc., H2 2016 17
Ocular Pain - Pipeline by Reata Pharmaceuticals, Inc., H2 2016 18
Ocular Pain - Pipeline by Sylentis S.A.U., H2 2016 19
Ocular Pain - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 20
Assessment by Monotherapy Products, H2 2016 21
Assessment by Combination Products, H2 2016 22
Number of Products by Stage and Target, H2 2016 24
Number of Products by Stage and Mechanism of Action, H2 2016 26
Number of Products by Stage and Route of Administration, H2 2016 28
Number of Products by Stage and Molecule Type, H2 2016 30
Ocular Pain - Dormant Projects, H2 2016 59